北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
作者: Hu, Yunfei1,2; Ding, Ning1; Jin, Xuan3; Feng, Lixia1; Ping, Lingyan1; Song, Yuqin1; Zhu, Jun1
关键词: Diffuse large B-cell lymphoma ; STAT3 ; Single nucleotide polymorphism ; Rituximab
刊名: CANCER CELL INTERNATIONAL
发表日期: 2014-03-13
DOI: 10.1186/1475-2867-14-25
卷: 14
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: ANTI-CD20 MONOCLONAL-ANTIBODY ; CHRONIC LYMPHOCYTIC-LEUKEMIA ; NON-HODGKINS-LYMPHOMA ; SIGNALING PATHWAY ; INTERFERON-ALPHA ; R-CHOP ; CANCER ; ACTIVATION ; SURVIVAL ; INHIBITION
英文摘要:

Background: Rituximab in the combination of CHOP chemotherapy has been widely used as the standard treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL). Inactivation of phosphorylation of STAT3 plays an essential role in rituximab-induced anti-proliferative activity in B-cell lymphoma. However, the relationship between STAT3 genetic polymorphisms and clinical response to standard frontline treatment with rituximab has not been well illustrated yet.

Methods: In this study we analyzed the STAT3 polymorphisms and prognosis of 166 diffuse large B-cell lymphoma (DLBCL) patients who were treated with rituximab from 2007 to 2010. Determination of the STAT3 polymorphisms of rs2293152 from genomic DNA was achieved by Sanger chain termination sequencing.

Results: We did not observe obvious correlation between patients′ disease features and STAT3 polymorphisms, but patients with homozygous genotypes at rs2293162 showed a trend of higher CR rate than those with the heterozygous genotype, especially in non-GCB subgroup (p = 0.011). Furthermore, homozygous genotypes GG and CC also showed advantages of long-term survival compared with heterozygous genotype patients (p = 0.022).

Conclusions: These results suggest that STAT3 polymorphisms could be a suitable biomarker related to clinical outcome of DLBCL patients treated with rituximab.

语种: 英语
所属项目编号: 81201873 ; 81241073 ; 7132050
项目资助者: NSFC ; Beijing Natural Science Foundation ; Peking University
WOS记录号: WOS:000334623400001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65131
Appears in Collections:北京大学临床肿瘤学院_淋巴肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Guizhou Canc Hosp, Guiyang Med Coll, Affiliated Hosp, Dept Oncol, Guiyang 550003, Peoples R China
3.Peking Univ, Hosp 1, Dept Internal Med Oncol, Beijing 100034, Peoples R China

Recommended Citation:
Hu, Yunfei,Ding, Ning,Jin, Xuan,et al. Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab[J]. CANCER CELL INTERNATIONAL,2014,14.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Hu, Yunfei]'s Articles
[Ding, Ning]'s Articles
[Jin, Xuan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Hu, Yunfei]‘s Articles
[Ding, Ning]‘s Articles
[Jin, Xuan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace